Patents by Inventor Kinya Nagata
Kinya Nagata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9233142Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: GrantFiled: June 2, 2014Date of Patent: January 12, 2016Assignees: National Hospital Organization Kinki-chuo Chest Medical center, AZBIO CorporationInventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Publication number: 20140308240Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: ApplicationFiled: June 2, 2014Publication date: October 16, 2014Applicants: NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER (27%), AZBIO CORPORATION (26%)Inventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Publication number: 20130011366Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for solving problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: ApplicationFiled: September 6, 2012Publication date: January 10, 2013Applicants: AZBIO CORPORATION (26%), NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER (27%)Inventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Patent number: 8288509Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: GrantFiled: April 24, 2009Date of Patent: October 16, 2012Assignees: National Hospital Organization Kinki-chuo Chest Medical center, AZBIO CorporationInventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Publication number: 20100015643Abstract: There is provided a method of quantitative determination using a flow cytometer, with which quantitative determination of cell surface protein can be effected more accurately than with current methods.Type: ApplicationFiled: May 21, 2007Publication date: January 21, 2010Inventors: Chuwa Tei, Kouji Orihara, Kinya Nagata, Ryutaro Oba, Hiroyuki Hirai
-
Publication number: 20090274651Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: ApplicationFiled: April 24, 2009Publication date: November 5, 2009Inventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Publication number: 20050239699Abstract: According to the present invention, there is provided a remedy for infections containing 15K granulysin as an active ingredient, which has no perceived side effect, and is effective.Type: ApplicationFiled: August 17, 2004Publication date: October 27, 2005Inventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Publication number: 20050144662Abstract: A knockout mouse whose genome includes an inactivated CRTH2 gene. The knockout mouse is obtained by subjecting to a serial passage a chimeric mouse originating from an early embryo to which a CRTH2-gene-knocked-out mouse embryonic stem cell has been introduced. Also disclosed is a detection method which includes employing, as an index, pathological condition of the knockout mouse to which the test substance has been administered, to thereby detect, in vivo, characteristics of a test substance in relation to CRTH2, or functions of CRTH2 in the living body.Type: ApplicationFiled: September 17, 2004Publication date: June 30, 2005Inventors: Masataka Nakamura, Kazuo Sugamura, Shoichi Takano, Kinya Nagata, Hiroyuki Hirai
-
Patent number: 6884593Abstract: An object of the present invention is to provide a method of identifying a substance which acts on a newly found second human prostaglandin D2 receptor subtype that differs from the DP receptor, and is useful for treating or preventing various diseases. In order to attain the object, the present invention provides a method of identifying properties of a test substance with respect to a human prostaglandin D receptor, by establishing correlation between the effect of a test substance on human CRTH2 with the effect of the test substance on the human prostaglandin D receptor.Type: GrantFiled: August 22, 2000Date of Patent: April 26, 2005Assignee: BML, Inc.Inventors: Hiroyuki Hirai, Kazuyuki Ogawa, Kinya Nagata, Syoichi Takano
-
Patent number: 6166186Abstract: The present specification provides a means for specifying the condition and type of immune-related diseases on the basis of knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More specifically, the gene (B19), specific only to the human Th2, is prepared by a subtraction method. A human-Th2-specific protein which the gene encodes is produced by recombinant methods, and a monoclonal antibody against the Th2-specific protein and a hybridoma which produces the monoclonal antibody is provided.Type: GrantFiled: January 10, 2000Date of Patent: December 26, 2000Assignee: BML, Inc.Inventors: Kazuyuki Ogawa, Kazuya Tanaka, Kinya Nagata, Syoichi Takano
-
Patent number: 6040426Abstract: The present invention provides for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More sepcifically, in this invention, the gene (B19) specific only the human Th2 is prepared and specified by a subtraction method, and a recombinant vector into which the gene is incorporated, a transformant transformed by the recombinant vector, a human-Th2-specific protein which the gene encodes and which derives from the transformant, and a monoclonal antibody against the Th2-specific protein are produced and the gene, protein, antibody, etc. are used as the means for specifying or correcting the polarization of the distribution of Th1 and Th2 to solve the above object.Type: GrantFiled: May 11, 1998Date of Patent: March 21, 2000Assignee: BML, Inc.Inventors: Kazuyuki Ogawa, Kazuya Tanaka, Kinya Nagata, Syoichi Takano
-
Patent number: 5962319Abstract: An element for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of distribution of Th1/Th2 subsets of helper T cells. The element for specifying or correcting the polarization of the Th1/Th2 subsets is implemented by use of a recombinant vector, a transformant, a human-Th1-specific protein, and an antibody which uses the human-Th1-specific protein as an antigen. A human-Th1-specific gene is prepared and specified by a subtraction technique and is incorporated into the recombinant vector. The transformant is formed by transforming the recombinant vector. The Th1-specific protein is encoded by the gene derived from the transformant.Type: GrantFiled: June 5, 1997Date of Patent: October 5, 1999Assignee: BML, Inc.Inventors: Kazuyuki Ogawa, Kazuya Tanaka, Kinya Nagata, Shoichi Takano